This brand name is authorized in Estonia, Japan, United States
The drug UPLIZNA contains one active pharmaceutical ingredient (API):
1
Inebilizumab
UNII 74T7185BMM - INEBILIZUMAB
|
Inebilizumab is a CD19-directed humanized afucosylated IgG1 monoclonal antibody produced by recombinant DNA technology. The precise mechanism by which inebilizumab exerts its therapeutic effects in neuromyelitis optica spectrum disorder (NMOSD) is unknown but is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, inebilizumab-cdon results in antibody-dependent cellular cytolysis. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
UPLIZNA Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
L04AG10 | L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: EE | Ravimiamet | Identifier(s): 1836547, 1881806 |
Country: JP | 医薬品医療機器総合機構 | Identifier(s): 6399429A1026 |
Country: US | FDA, National Drug Code | Identifier(s): 72677-551 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.